Effects of cyclodextrins on RBC aggregation and blood viscosity

Clinical Hemorheology and Microcirculation

Volumn 36, Issue 2, 2007, Pages 173-180

  Toyama, Yoshiharu ^a,b   Pais, Eszter ^a   Meiselman, Herbert J ^a   Alexy, Tamas ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Aggregation; Cyclodextrins; Hemorheology; Platelets; Red blood cell

Indexed keywords

ALPHA CYCLODEXTRIN; BETA CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; GAMMA CYCLODEXTRIN;

ARTICLE; BLOOD ANALYSIS; BLOOD RHEOLOGY; BLOOD SAMPLING; BLOOD VISCOSITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ERYTHROCYTE AGGREGATION; HEMATOCRIT; HUMAN; INCUBATION TIME; NORMAL HUMAN; SHEAR FLOW; SHEAR RATE; THROMBOCYTE ADHESIVENESS; THROMBOCYTE KINETICS; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; VOLUNTEER;

BLOOD VISCOSITY; CELL CULTURE TECHNIQUES; CYCLODEXTRINS; ERYTHROCYTE AGGREGATION; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 33847337421     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, Brit. Med. J. 324 (2002), 71-86.
2. T. Alexy, A. Toth, Zs. Marton et al., Inhibition of ADP-evoked platelet aggregation by selected poly(ADP-ribose) polymerase inhibitors, J. Cardiovasc. Pharmacol. 43 (2004), 423-431.
3. T. Alexy, R.B.Wenby, E. Pais, L.J. Goldstein,W. Hogenauer, H.J. Meiselman, An automated tube-type blood viscometer: validation studies, Biorheology 42 (2005), 237-247.
4. J.K. Armstrong, H.J. Meiselman, T.C. Fisher, Evidence against macromolecular "bridging" as the mechanism of red blood cell aggregation induced by nonionic polymers, Biorheology 36 (1999), 433-437.
5. F.A. Baglia, C.N. Shrimpton, J.A. Lopez, P.N. Walsh, The Glycoprotein Ib-IX-V complex mediates localization of factor XI to lipid rafts on the platelet membrane, J. Biol. Chem. 278 (2003), 21744-21750.
6. O.K. Baskurt, E. Levi, S. Caglayan et al., The role of hemorheologic factors in the coronary circulation, Clin. Hemorheol. 11 (1991), 121-127.
7. H. Baumler, B. Neu, R. Mitlohner, R. Georgieva, H.J. Meiselman, H. Kiesewetter, Electrophoretic and aggregation behavior of bovine, horse and human red blood cells in plasma and in polymer solutions, Biorheology 38 (2001), 39-51.
8. G.V.R. Born and M.J. Cross, The aggregation of blood platelets, J. Physiol. 168 (1963), 178-195.
9. CAPRIE Steering Committee, A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE), Lancet 348 (1996), 1329-1339.
10. C. Carter, D. McGee, D. Reed, K. Yano and G. Stemmermann, Hematocrit and the risk of coronary heart disease: The Honolulu Heart Program, Am. Heart J. 105 (1983), 674-679.
11. Y.I. Cho,W.T. Kim and K.R. Kensey, A new scanning capillary tube viscometer, Rev. Sci. Instrum. 70 (1999), 2421-2423.
12. B. Chong-Martinez, T.A. Buchanan, R.B. Wenby and H.J. Meiselman, Decreased red blood cell aggregation subsequent to improved glycemic control in type 2 diabetes mellitus, Diabet. Med. 20 (2003), 301-306.
13. H.H. Donaubauer, H. Fuchs, K.H. Langer and A. Bar, Subchronic intravenous toxicity studies with γ-cyclodextrin in rats, Regul. Toxicol. Pharmacol. 27 (1998), 189-198.
14. J. Dormandy, Cardiovascular diseases, in: Clinical Hemorheology, S. Chien, J. Dormandy, E. Ernst and A. Matrai, eds, Martinus Nijhoff Publishers, Dordrecht, 1987, pp. 165-194.
15. Y. Ezumi, K. Kodama, T. Uchiyama and H. Takayama, Constitutive and functional association of the platelet collagen receptor glycoprotein VI-Fc receptor γ-chain complex with membrane rafts, Blood 99 (2002), 3250-3255.
16. Joint FAO/WHO Experts Committee on Food Additives, 44th meeting, 1998, Geneva, Switzerland.
17. V. Fuster, M.L. Dyken, P.S. Vokonas and C. Hennekens, Aspirin as a therapeutic agent in cardiovascular disease, Circulation 87 (1993), 659-675.
18. K. Gousset, W.F. Wolkers, N.M. Tsvetkova et al., Evidence for a physiological role for membrane rafts in human platelets, J. Cell. Physiol. 190 (2002), 117-128.
19. K. Gousset, N.M. Tsvetkova, J.H. Crowe, F. Tablin, Important role of raft aggregation in the signaling events of cold-induced platelet activation, Biochim. Biophys. Acta 1660 (2004), 7-15.
20. S. Grgurevich, R. Krishnan, M.M. White and L.K. Jennings, Role of in vitro cholesterol depletion in mediating human platelet aggregation, J. Thromb. Haemost. 1 (2003), 576-586.
21. RISC Group, Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease, Lancet 336 (1990), 827-830.
22. T. Irie, M. Otagiri, M. Sunada et al., Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro, J. Pharm. Dyn. 5 (1982), 741-744.
23. G. Kesmarky, K. Toth, L. Habon, G. Vajda and I. Juricskay, Hemorheological parameters in coronary artery disease, Clin. Hemorheol. Microcirc. 18 (1998), 245-251.
24. G. Kesmarky, K. Toth, G. Vajda, L. Habon, R. Halmosi and E. Roth, Hemorheological and oxygen free radical associated alterations during and after percutaneous transluminal coronary angioplasty, Clin. Hemorheol. Microcirc. 24 (2001), 33-41.
25. H. Kogure, M. Kitazawa, Y. Toyama, K. Kubota and M. Ochiai, Effects of saccharides on the fibrinogen-fibrin conversion by thrombin, Trans. MRS-J. 28 (2003), 949-952.
26. B.A.R. Lina and A. Bar, Subchronic (13-week) oral toxicity study of ?-cyclodextrin in dogs, Regul. Toxicol. Pharmacol. 39 (2004), S27-S33.
27. T. Loftsson, Increasing the cyclodextin complexation of drugs and drug bioavailability through addition of water soluble polymers, Pharmazie 53 (1998), 733-740.
28. G.D.O. Lowe, Clinical Blood Rheology, CRC Press, Boca Raton, 1988.
29. I.C. Munro, P.M. Newberne, V.R. Young and A. Bar, Safety assessment of γ-cyclodextrin, Regul. Toxicol. Pharmacol. 39 (2004), S3-S13.
30. B. Neu and H.J. Meiselman, Depletion-mediated red blood cell aggregation in polymer solutions, Biophys. J. 83 (2002), 2482-2490.
31. B. Neu, S.O. Sowemimo-Coker and H.J. Meiselman, Cell-cell affinity of senescent human erythrocytes, Biophys. J. 85 (2003), 75-84.
32. Y. Ohtani, T. Irie, K. Uekama, K. Fukunaga and J. Pitha, Differential effects of α-, β- and γ-cyclodextrins on human erythrocytes, Eur. J. Biochem. 186 (1989), 17-22.
33. T.M. Quinton, S. Kim, J. Jin and S.P. Kunapuli, Lipid rafts are required in Galpha(i) signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation, J. Thromb. Haemost. 3 (2005), 1036-1041.
34. M.W. Rampling, Hyperviscosity as a complication in a variety of disorders, Semin. Thromb. Hemost. 29 (2003), 459-465.
35. M.W. Rampling, H.J. Meiselman, B. Neu and O.K. Baskurt, Influence of cell-specific factors on red blood cell aggregation, Biorheology 41 (2004), 91-112.
36. S.K. Rodal, G. Skretting, O. Garred, F. Vilhardt, B. van Deurs and K. Sandvig, Extraction of cholesterol with methyl-betacyclodextrin perturbs formation of clathrin-coated endocytic vesicles, Mol. Biol. Cell 10 (1999), 961-974.
37. T. Somer and H.J. Meiselman, Disorders of blood viscosity, Ann. Med. 25 (1993), 31-39.
38. J.F. Stoltz, M. Singh and P. Riha, Hemorheology in Practice, IOS Press, Amsterdam, 1999.